PT - JOURNAL ARTICLE AU - Huang, Ching-I AU - Crump, Ronald E AU - Brown, Paul AU - Spencer, Simon E F AU - Miaka, Erick Mwamba AU - Shampa, Chansy AU - Keeling, Matt J AU - Rock, Kat S TI - Shrinking the gHAT map: identifying target regions for enhanced control of <em>gambiense</em> human African trypanosomiasis in the Democratic Republic of Congo AID - 10.1101/2020.07.03.20145847 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.03.20145847 4099 - http://medrxiv.org/content/early/2020/07/04/2020.07.03.20145847.short 4100 - http://medrxiv.org/content/early/2020/07/04/2020.07.03.20145847.full AB - Background Gambiense human African trypanosomiasis (gHAT) is a disease targeted for elimination of transmission (EOT) by 2030, however the likelihood of achieving it is unknown. We utilised modelling to study the impact of currently-available intervention methods on transmission across the Democratic Republic of Congo (DRC) – which accounts for ∼ 70% of global burden – and highlight regions requiring intensified interventions.Methods A model previously fitted to case data in DRC was used to predict cases and new infections under four future strategies in 168 health zones. The strategies comprise of medical interventions – active and passive screening (AS and PS) and some include large-scale vector control (VC). In each health zone, we estimate the median year of EOT and the probability of EOT by 2030 under each and compute the least ambitious strategy predicted to achieve EOT by 2030.Findings The model predicts 42 health zones are very likely to achieve EOT (&gt; 90% probability) using medical-only strategies continued at mean coverage levels; this increases to 52 when AS coverage is increased to maximum previous coverage. In all VC strategies, health zones are predicted to meet EOT by 2030, although there are several where increasing low AS coverage could achieve this.Interpretation This analysis provides a priority list for consideration for supplementary VC implementation (Bagata, Bandundu, Bolobo, Kikongo, Kwamouth and Masi Manimba in former Bandundu province) in conjunction with the recent AS coverage.Funding Bill Melinda Gates Foundation [OPP1177824, OPP1184344, OPP1156227, OPP1186851, and OPP1155293] and Belgian Development Agency (ENABEL).Evidence before this study On 30th April 2020 we searched PubMed and ScienceDirect to identify previous predictive modelling studies of gHAT in DRC using the search terms “model” AND “Democratic Republic of Congo” OR “DRC” AND “try-panosomiasis” OR “sleeping sickness”. There are numerous modelling studies which have looked at estimating the impact of a variety of strategies on transmission and elimination, however many utilise infection prevalence categories for performing simulations rather than location-specific data. For DRC, modelling studies have made projections at a province-level (i.e. Bandundu), and for health zones (i.e all of Equateur and some in Bandundu), concluding that there is high heterogeneity in underlying transmission, consequently whether medical-only strategies will suffice to meet elimination of transmission (EOT) by 2030. They find that supplemental, large-scale vector control would be expected to result in rapid EOT across settings. Two high-endemicity, village-level studies suggest that regular, high-coverage screening is needed to achieve EOT within 15 years without additional interventions.Added value of this study This study presents predictions for EOT across the whole DRC for the first time. Since DRC has the highest disease burden it is critical to understand how far current tools might go towards achieving this 2030 target across the country, and how strategies may need to be adapted for specific locations in the endgame. It also provides a priority list for regions requiring intensified interventions.Implications of all the available evidence Our analysis suggests that, whilst many regions of DRC are expected to meet the EOT goal by 2030 with medical-only strategies, for some regions current strategies may need to be bolstered to achieve EOT within the next decade. Although some regions could consider increasing coverage of active screening, vector control appears a desirable supplemental intervention in several specific high-prevalence locations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Bill and Melinda Gates Foundation (www.gatesfoundation.org) through the Human African Trypanosomiasis Modelling and Economic Predictions for Policy (HAT MEPP) project [OPP1177824] (CH, REC, PB, KSR, and MJK), through the NTD Modelling Consortium [OPP1184344, OPP1156227, and OPP1186851] (KSR, SEFS, and MJK), and through the TRYP-ELIM project [OPP1155293] (EMM and CS) and the Belgian Development Agency (ENABEL) (EMM and CS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe gHAT data were obtained from the WHO HAT Atlas and are subject to a data sharing agreement. Interested parties should apply to WHO in order to gain access to these data. Results for each health zone level projection can be viewed on the paper's companion website. Code and model outputs are available from the OSF. https://hatmepp.warwick.ac.uk/projections/v1 https://osf.io/jza27/?view_only=d523cb1edf9c4828bc63cb197e5000b2